We are building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases as monotherapy or combination therapies, and in advancing these therapies, we aim to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

Our TYK2 franchise is led by ESK-001, a TYK2 inhibitor currently in clinical development for moderate to severe plaque psoriasis and systemic lupus erythematosus (SLE). This highly selective inhibitor has the potential to effectively treat multiple immune-mediated indications.

We are also developing A-005, a CNS-penetrating, allosteric TYK2 inhibitor for neuro-inflammatory diseases such as multiple sclerosis (MS).

Beyond TYK2, we have several earlier-stage discovery assets, comprised of targets identified by our precision data analytics platform, for the potential treatment of immune-mediated indications. 

About ESK-001

A highly selective allosteric TYK2 inhibitor with a differentiated pharmacological profile

Our lead candidate ESK-001, a highly selective tyrosine kinase 2 (TYK2) inhibitor, is being evaluated in Phase 3 clinical trials for the treatment of patients with moderate to severe plaque psoriasis and a Phase 2b clinical trial for the treatment of systemic lupus erythematosus (SLE).

clinical Programs

About A-005

A central nervous system penetrant allosteric TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases

We are also developing A-005, our second TYK2 inhibitor with differentiated properties for neuro-inflammatory diseases. Our data analytics demonstrate a genetic rationale for TYK2 inhibition in diseases of the central nervous system (CNS).

Additional Programs / Discovery Efforts

Beyond TYK2, we have several earlier-stage discovery assets comprised of targets identified by our precision data analytics platform for the potential treatment of immune-mediated indications.